DK4171559T3 - Arimoclomol til behandling af Gauchers sygdom - Google Patents

Arimoclomol til behandling af Gauchers sygdom

Info

Publication number
DK4171559T3
DK4171559T3 DK21733160.2T DK21733160T DK4171559T3 DK 4171559 T3 DK4171559 T3 DK 4171559T3 DK 21733160 T DK21733160 T DK 21733160T DK 4171559 T3 DK4171559 T3 DK 4171559T3
Authority
DK
Denmark
Prior art keywords
arimoclomol
treatment
gaucher disease
gaucher
disease
Prior art date
Application number
DK21733160.2T
Other languages
Danish (da)
English (en)
Inventor
Thomas Kirkegaard Jensen
Linda Ingemann
Cathrine Kolster Fog-Tønnesen
Dali Christine Í
Anders Mørkeberg Hinsby
Original Assignee
Zevra Denmark As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zevra Denmark As filed Critical Zevra Denmark As
Application granted granted Critical
Publication of DK4171559T3 publication Critical patent/DK4171559T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK21733160.2T 2020-06-24 2021-06-24 Arimoclomol til behandling af Gauchers sygdom DK4171559T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20182067 2020-06-24
PCT/EP2021/067366 WO2021260120A1 (en) 2020-06-24 2021-06-24 Arimoclomol for treating gaucher disease

Publications (1)

Publication Number Publication Date
DK4171559T3 true DK4171559T3 (da) 2025-12-15

Family

ID=71143584

Family Applications (1)

Application Number Title Priority Date Filing Date
DK21733160.2T DK4171559T3 (da) 2020-06-24 2021-06-24 Arimoclomol til behandling af Gauchers sygdom

Country Status (14)

Country Link
US (1) US20230226036A1 (cg-RX-API-DMAC7.html)
EP (1) EP4171559B1 (cg-RX-API-DMAC7.html)
JP (3) JP2023531750A (cg-RX-API-DMAC7.html)
KR (1) KR20230035586A (cg-RX-API-DMAC7.html)
CN (1) CN116075305A (cg-RX-API-DMAC7.html)
AU (1) AU2021295437A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022026396A2 (cg-RX-API-DMAC7.html)
CA (1) CA3183559A1 (cg-RX-API-DMAC7.html)
DK (1) DK4171559T3 (cg-RX-API-DMAC7.html)
ES (1) ES3056005T3 (cg-RX-API-DMAC7.html)
IL (1) IL299250A (cg-RX-API-DMAC7.html)
MX (1) MX2023000033A (cg-RX-API-DMAC7.html)
PT (1) PT4171559T (cg-RX-API-DMAC7.html)
WO (1) WO2021260120A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9662375B2 (en) * 2010-11-30 2017-05-30 Orphazyme Aps Methods for increasing intracellular activity of Hsp70

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222994B1 (hu) 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HUP9900475D0 (en) 1999-02-26 1999-04-28 Biorex Kutato Fejlesztoe Kft O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
HUP0001583A2 (hu) 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
JP5616336B2 (ja) * 2008-06-26 2014-10-29 オルファザイム エーピーエスＯｒｐｈａｚｙｍｅ Ａｐｓ 酵素活性の調節因子としてのＨｓｐ７０の使用
AU2010281403B2 (en) * 2009-07-28 2016-03-10 Takeda Pharmaceutical Company Limited Compositions and methods for treating Gaucher disease
US10709700B2 (en) * 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
ES2831764T3 (es) * 2016-04-29 2021-06-09 Orphazyme As Arimoclomol para el tratamiento de trastornos asociados a glucocerebrosidasa
KR102279347B1 (ko) * 2016-12-15 2021-07-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
IL299250A (en) 2023-02-01
AU2021295437A1 (en) 2023-02-02
EP4171559A1 (en) 2023-05-03
BR112022026396A2 (pt) 2023-03-14
KR20230035586A (ko) 2023-03-14
MX2023000033A (es) 2023-04-10
WO2021260120A1 (en) 2021-12-30
JP7849574B2 (ja) 2026-04-21
JP2026042936A (ja) 2026-03-11
JP2023531750A (ja) 2023-07-25
EP4171559B1 (en) 2025-09-10
ES3056005T3 (en) 2026-02-17
CN116075305A (zh) 2023-05-05
CA3183559A1 (en) 2021-12-30
PT4171559T (pt) 2025-12-16
US20230226036A1 (en) 2023-07-20
JP2026104910A (ja) 2026-06-25

Similar Documents

Publication Publication Date Title
EP4149460C0 (en) THERAPEUTIC SOLID DOSAGE FORMS
DK3277815T3 (da) Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser
DK3681500T3 (da) Anvendelse af pilocarpinhydrochlorid til behandling af presbyopi
DK3700529T3 (da) Ny kombination af aktive midler til behandling af progressive fibroserende interstitielle lungesygdomme (pf-ild)
JP1671730S (ja) 医療用加湿器用タブ用部品
DK3328864T3 (da) Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser
EP3751048A4 (en) FIBER TREATMENT AGENTS
EP3758633A4 (en) IMPLANTS AND METHODS OF USE AND ASSEMBLY
EP4041064A4 (en) A medical therapeutic device
IL272418A (en) Obinutuzumab treatment of a dlbcl patient subgroup
EP4493175A4 (en) MIRDAMETINIB TREATMENT
EP3911941C0 (en) FABRIC GHOSTS
IL280227A (en) Arimoclomol for treating glucocerebrosidase associated disorders
PL3697399T3 (pl) Środki terapeutyczne do zastosowania w leczeniu zespołu niespokojnych nóg
EP4203928A4 (en) Inhalable therapeutic agents
IL312635A (en) Pharmaceutical combinations for treatment of hbv
DK3403674T3 (da) Farmaceutiske sammensætninger til behandling af smerte
EP3960924C0 (en) CLOTHING TREATMENT DEVICE
EP3796928A4 (en) Treatment of gaucher disease
IL325421A (en) Combinational treatment
EP3983050A4 (en) Medicament containment devices and associated compositions
EP4398893A4 (en) IBOGAINE COMBINATION THERAPY
EP4405465A4 (en) TREATMENT METHODS
LT3743043T (lt) Farmacinės kompozicijos, skirtos pooperacinio skausmo gydymui
DK3574912T3 (da) Sammensætning til behandling af diabetisk sygdom